Skip to main content

Table 2 Intervention

From: Sclerotherapy and prolotherapy for chronic patellar tendinopathies - a promising therapy with limited available evidence, a systematic review

Author

Year

Study Type

Substance

Control

Mean VAS

Mean no of injections

Serious Adverse Events

     

pre

post

FU

  

Sclerotherapy

 Alfredson

2004

prospective

polidocanol 5 mg/ml

na

79.7

19

 

2.7

none

 Gisslén

2006

casereport

polidocanol 10 mg/ml

na

90

0

0

1.0

none

 Hoksrud

2006

RCT

polidocanol 10 mg/ml

adrenaline 5 μg/ml+lidocaine hcl 5 mg/ml

VISA

VISA

VISA

3.1 (intervention + crossover)

none

 Willberg

2011

RCT

polidocanol 10 mg/ml

arthroscopic shaving

69

41.1

(17)

na

none

 Hoksrud

2012

prospective

polidocanol 10 mg/ml

na

VISA

VISA

VISA

2.5

none

Prolotherapy

 Ryan

2011

prospective

25% dextrose solution

na

51.1

 

25.8

median 4

none

 Topol

2011

RCT

12.5% dextrose solution

lidocaine 10 mg/ml

NPPS

NPPS

NPPS

3.8

none

  1. VAS Visual Analogue Scale, no number, FU Follow-up, RCT Randomized controlled trial, na not available, VISA Victorian Institute of Sport Assessment, NPPS Nirschl Pain Phase Scale